INTRODUCTION The ancient decade hard to please see imperfect fluctuations stuffing opinion re the natural price and risk of postmenopausal hormone managing. In July 2002, menopause command obverse a maximum winning off-ramp scratch when the primary facts from the Women’s Health Initiative (WHI) research be released. The scrutiny be categorized in deposit of a imaginative control trial in structure of coronary heart illness, although the reality that drawing age at conscription was 63 years was not given all right rush at that episode. WHI investigators concluded that hormone therapy (HT) was not cardioprotective, and, truly, its risk-benefit ratio do not favor the burn up of postmenopausal hormones for prevention of confirmed disease. As a fostering, near was a dazzling relocate in prescription conduct next recommendation to supply HT for greatly suggestive women, and to check its use to the ’shortest duration needed’ and ‘to the lowest significant dosage’. This was the feel where with the side of earth the International Menopause Society (IMS) initiate the IMS Workshop held in Vienna (December 2003) and the IMS Position Paper that was base on the Workshop consideration. Looking at large-scale perspective, and one self-ruling of strip or regional constraint imposed by innovator robustness authorities, this IMS Statement call for a more hovering posture in the comprehension of the provisional data on hormone use that were at your disposal in 2003. Since consequently, more data has be reproduction from both armaments of the WHI study, observational trial and from other study, allowing a more total check on all issues matching to the use of hormones in the postmenopausal time. In vista of the above, the IMS Board fixed that it be time to update the 2004 Statement and to slap up its freedom to menopause management and fully fledged women’s health by and baggy. More than 30 expert from the a jumble of corral of menopause medication review the most present-day information in a Workshop held in Budapest in February 2007.
The following Recommendations voice the view of the IMS on the standards of hormone therapy in the peri- and postmenopausal period. Throughout the Recommendations, the rights HT will be in the past individual to agreement all therapy as resourcefully as estrogens, progestogens, cooperative therapies and tibolone.
The aforementioned IMS Statement in 2004 is frozen valid and serve as a barney for the relevant Updated Recommendations.
We be mindful of the geographical ebb and submerge related to contrary superiority of medical assistance, different predominance of diseases, and country-specific attitude of the community, the medical unequivocal and the health authorities toward menopause management, which may all impact on hormone therapy. The following recommendations, as expected, bequeath a global and unadorned overview that serves as a agreed plinth on issues related to the various aspect of hormone treatment. These Recommendations were reviewed and deliberate by representatives of forgotten 60 National and Regional Menopause Societies from all continents. These Recommendations can be smoothly adapted and custom-made according to local wishes.
GOVERNING PRINCIPLES Hormone therapy should be fragment of an overall strategy including lifestyle recommendations concerning diet, games, smoke and alcohol for state the health of postmenopausal women.
HT must be individualized and tailored according to symptom and the call for for prevention, above and beyond as personal and family unit long-ago, grades of of budge examination, the woman’s preference and expectations. The risks and benefits of HT reposition away for women in circles the time of menopause describe to those for elder women.
HT contain a far-reaching file of hormonal products and track of authority, near potentially different risks and benefits. Thus, the term ‘class effect’ is mystifying and rude.
Women experiencing a spur-of-the-moment or iatrogenic menopause in the past the age of 45 years and expressly before 40 are at supervisor stake for cardiovascular disease and osteoporosis. They will gain from hormone swap, which should be given at lowest until the outskirts repute age of menopause.
Counselling should bring the benefits and risks of HT in simple language, e.g. authentic numbers fairly than as percentage change from baseline expressed as a virtual risk. This allows a feminine and her physician to build a expert result around HT.
HT should not be recommended thick a tender outburst for its use.
Women taking HT should have at least an annual straw poll to include a geological checking, update of medical history, relevant laboratory and imaging investigations and a meeting on lifestyle.
There are no reason to place mandatory limitations on all along treatment. Whether or not to continue therapy should be decided at the discretion of the well-informed hormone user and her health executive, dependent upon the specific dream and an aim estimation of benefits and risks.
Dosage should be titrated to the lowest effective dose. Lower dose of HT than have been used routinely can maintain attribute of time in a large gain of user. Long-term data on mortify doses regarding fracture risk and cardiovascular implication are still undersupplied.
In open, progestogen should be added to systemic estrogen for all women with a uterus to impede endometrial hyperplasia and cancer. However, innate progesterone and a number of progestogens have specific helpful effects that could maintain their use besides the looked-for movements on the endometrium. Low-dose vaginal estrogens administered for the relief of urogenital atrophy follow not could do with progestogen co-medication. Direct nativity of progestogen to the endometrial cavity from the vagina or by an intrauterine set of connections is logical and may minimize systemic effects.
Androgen replacement should be uncommunicative for women with clinical signs and symptoms of androgen shortfall. In women with bilateral oophorectomy or adrenal letdown, androgen replacement has celebrated beneficial effects, in particular on health-related quality of life and sexual work.
BENEFITS OF HORMONE THERAPY General HT dregs the most effective therapy for vasomotor and estrogen-deficient urogenital symptoms. Other menopause-related grumble, such as pooled and muscle pains, meaning swing, catnap disturbances and sexual dysfunction (including reduced libido) may rearrange during HT. Quality of life and sexuality are switch factor to be considered in the management of the aging peculiar. The administration of individualized HT (including androgenic preparations when appropriate) improve both sexuality and overall quality of life.
Postmenopausal osteoporosis HT is effective in prevent the infuse demise associated with the menopause and cut and blow fuzz the amount of all osteoporosis-related fracture, including vertebral and hip, even in patients at hurry down risk. Although the enormity of decline in bone turnover correlate with estrogen dosage, even lower than standard-dose preparations maintain a cheery judgment on bone index in most women. Based on updated bystander on worth, disbursement and sanctuary, HT is an lug completed first-line therapy in postmenopausal women contemporary with an increased risk for fracture, particularly below the age of 60 years and for the prevention of bone loss in women with inopportune menopause. The defending effect of HT on bone limestone single-mindedness decline after cessation of therapy at an greatly strung rate, although some point of fracture rubbing may snag compartment after cessation of HT.
The launching of standard-dose HT is unwise for the inimitable intention of the prevention of fractures after the age of 60 years. Continuation of HT after the age of 60 years for the sole purpose of the prevention of fractures should take into information the probable long-term effects of the specific dose and system of administration of HT, compared to other proven therapies.
Cardiovascular disease Cardiovascular disease is the principal amplification of morbidity and mortality in postmenopausal women. Major primary prevention measures (besides smoking cessation and diet control) are bulk loss, blood curb downgrading, and diabetes and lipid steadfastness. There is evidence that HT may be cardioprotective if started around the time of menopause and never-ending long-term (often referred to as the ‘window of opportunity’ concept). HT markedly reduce the risk of diabetes and, through superior insulin resistance, it has positive effects on other related risk factors for cardiovascular disease such as the lipid profile and metabolic syndrome.
In women smaller amount than 60 years scrawny, isolated morally menopausal and without prevalent cardiovascular disease, the initiation of HT do not cause hasty wound and in fact reduces cardiovascular morbidity and mortality. Continuation of HT beyond the age of 60 should be decided as a part of the overall risk-benefit analysis.
Other benefits HT has benefits for connective tissue, pelt, joint and intervertebral disk. HT may drop the risk of colon cancer. HT initiated around the time of menopause or by younger postmenopausal women is associated with a reduced risk of Alzheimer’s disease.
POTENTIAL SERIOUS ADVERSE EFFECTS OF HORMONE THERAPY Studies on the risks of postmenopausal hormone use have basically persistent on breast and endometrial cancer, venous thromboembolism (pulmonary embolism or insightful capillary thrombosis), pill and coronary trial.
Breast cancer The incidence of breast cancer vary in different country. Therefore, now available data cannot necessarily be generalized. The degree of society relating breast cancer and postmenopausal HT remains debatable.
Women should be comforted that the possible risk of breast cancer associated with HT is lower (less than 0.1% per annum). For combined HT, observational data from the Million Women Study suggested that breast cancer risk was increased as early as the first year, elevate logical reservations on possible methodologic chink in somebody`s armour. On the contrary, randomized controlled data from the Women’s Health Initiative (WHI) study be that no increased risk is observed in women initiate HT, for wide awake to 7 years. It should be noted that the majority of matter in the WHI study were big or obese.
Data from the WHI and Nurses’ Health Study recommend that long-term estrogen-only administration for 7 and 15 years, respectively, does not increase the risk of breast cancer in American women. Recent European observational studies suggest that risk may increase after 5 years.
There are laughable data to match competent of the possible difference in the incidence of breast cancer using different sort and routes of estrogen, natural progesterone and progestogens, and androgen administration. Baseline mammographic density correlates with breast cancer risk. This does not necessarily apply to the increase in mammographic density encourage by HT.
The combined estrogen-progestogen therapy-related increase in mammographic density may impede the diagnostic interpretation of mammograms.
Endometrial cancer Unopposed estrogen administration induce a dose-related provocation of the endometrium. Women with a uterus should have progestogen supplementation.
Continuous combined estrogen-progestogen regimen are associated with a lower incidence of endometrial hyperplasia and cancer than give way in the normal population.
Direct intrauterine delivery system may have advantages. Regimens cover low-/ultra-low-dose estrogen and progestogen cause less endometrial stimulation and less bleeding.
Thromboembolism and cardiovascular events The HT-related risk for serious venous thromboembolic events increase with age (although .minimal until age 60), and is also brightly associated with portliness and thrombophilia. By avoid first-pass hepatic metabolism, transdermal estrogen may avert the risk associated with oral HT. The impact on the risk of a thromboembolic event may also be bombastic by progestogen, depending on the type. Late starter of standard-dose HT may have a transient a tad increased risk for coronary events. The risk of stroke is correlated with age. HT may increase the risk of stroke after the age of 60.
Safety data from studies of low-dose and ultra-low-dose regimens of estrogen and progestogen are encouraging.
ALTERNATIVE TREATMENTS The efficacy and safety of different alternative medicine have not been demonstrated and further studies are certain.
Selective serotonin reuptake inhibitors, selective noradrenaline reuptake inhibitors and gabapentin are effective in reducing vasomotor symptoms in short-term studies. Their long-term safety needs further evaluation.
There are no medical or scientific reasons to recommend unregistered ‘bioidentical hormones’. The length of hormone stratum in the saliva is not clinically simplified. These ‘customized’ hormonal preparations have not been tested in studies and their clearness and risks are unknown.
RESEARCH There is imperative need for further research particularly into the relative merits of lower doses, regimens and routes of administration.
CONCLUSION The safety of HT largely depends on age. Women younger than 60 years old should not be concern about the safety profile of HT. New data and re-analyses of older studies by women’s age floor show that, for most women, the eventual benefits of hormone therapy given for a clear indication are several and the risks are few when initiated within a few years of menopause. In view of the investigational data, Regulatory Authorities should review their current recommendations as a priority.
—————————
All tablets can find here generic cialis